SENSEONICS HOLDINGS INC. overview

Thinking about buying stock in Senseonics Holdings, Ainos, Marpai, Rush Street Interactive, or Evgo? PR Newswire NEW YORK, March 8, 2024 NEW YORK , March 8, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SENS, AIMD, MRAI, RSI, and EVGO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. SENS:...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended June 30, 2023. Recent Highlights & Accomplishments: Generated revenue of $4.1 million in the second quarter of 2023 Submitted an application to the FDA for an iCGM designation for the Eversense CGM system Received a positive...

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, August 10, 2023. Management will hold a conference call to review the Company’s second quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section 711(a). On July 3, 2023, Senseonics Compensation Committee granted 4 new non-executive employees non-qualified...

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today highlighted new clinical data presented at the American Diabetes Association 83 rd Scientific Session. Two studies were presented demonstrating the safety and accuracy of the Eversense E3 CGM system. “These data further bolster Eversense’s position as a leading CGM...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that UnitedHealthcare, the largest health insurance company in the United States, will begin providing coverage for the Eversense E3 CGM System effective July 1, 2023 for people with type 1 and insulin-requiring type 2 diabetes. "The policy update from...